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ABSTRACT 
 
The aim of this study was to style an oral sustained release matrix tablet of highly water soluble biguanide 
anti diabetic drug. The matrix tablets are prepared by melt granulation method using HPMC K 200M as hy-
drophilic drug release retarding polymer, and octadecanoic acid as melt able binder also as hydrophobic 
carrier. The drug and excipients compatibility was studied by FTIR. The formulated matrix tablets were 
characterized for physical parameters and in vitro dissolution profile. FTIR spectra revealed the absence of 
drug excipients interaction. The physical parameters of the tablets were found within the bounds . The drug 
release kinetics demonstrated that by increasing the concentration of hydrophilic polymer and hydrophobic 
carrier the drug release rate was retarded proportionally. Kinetic modelling of in - vitro release profile re-
vealing that the drug release from the matrix tablets following first order kinetics, and therefore the drug 
release mechanism of optimized (F7) formula following non fickian transport mechanism. Accelerated sta-
bility studies were performed consistent with ICH guide lines. Temperature 40 ± 20oC and ratio 75±5% RH 
to review physical and chemical changes of formulation. No physical or chemical changes were observed 
after t accelerated stability studies. 
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INTRODUCTION 
Sustained release dosage forms are dosage forms de-
signed to release (liberate) a drug at a predetermined 
rate so as to take care of a continuing drug concentra-
tion for a selected period of your time with mini-
mum side effect. The perfect drug delivery system 
have two things would be required first it might be 
one dose the duration of treatment whether it’s for 
days or week, like lifetime of the patient as in hyper-
tension or diabetes. Second it should deliver the ac-
tive entity on to the location of the action, thereby 
minimizing side effects.[1]  
Advantages of sustained release dosage forms: 
1. Control of drug therapy is achieved  
2. Rate and extent of drug absorption are often 
modified. 
3. Frequency of drug administration is reduced. 
Disadvantages of sustained release dosage 
forms:[2] 
1. It don’t promote prompt termination of ther-
apy 
2. Less flexibility in dose adjustment 
Oral route of administration is taken into account as 
widely accepted route thanks to ease inconvenience 
by self-administration, compactness, and simple 
manufacturing process. It had been observed that 
drugs administered by oral route produce 90% of 
systemic effects. Conventional dosage form produces 
the wide selection of fluctuation in drug concentra-
tion in bloodstream which results in a loss in drug ef-
fectiveness or increases the incidence of side effects 
with subsequent undesirable toxicity and poor effi-
ciency. However, sustained or controlled drug deliv-
ery systems differ by conventional dosage forms 
thereby decreasing the frequency of the dosing and 
also increases effectiveness of the drug by localiza-
tion at the site of action, reducing the dose required 
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and providing uniform drug delivery. Sustained re-
lease preparations are helpful to scale back the dos-
age frequency and side effects of medicines and im-
prove patient’s convenience. Sustained release ma-
trix tablet is comparatively easy to fabricate by incor-
porating the drug in slowly dissolving or inert porous 
polymer materials.[3] 
Drug release through matrix system is set by water 
penetration, polymer swelling, drug dissolution, drug 
diffusion, and matrix erosion that lead to a rapid for-
mation of external layer, allowing drug release modi-
fication. Hydrophilic matrices are becoming popular 
in controlling the discharge of soluble drugs from 
solid dosage forms. These systems appear to be one 
of the foremost attractive approaches from an eco-
nomic also as from the tactic development points of 
view. The use of mixtures of polymers represents a 
possible way of achieving required release proper-
ties. Mixtures of varied non-ionic cellulose ethers are 
used to give different viscous efficiencies. The fore-
most widely used polymer for hydrophilic matrices is 
hydroxyl propyl methylcellulose (HPMC). This poly-
mer is taken under consideration among the water-
soluble polymers. Ethyl cellulose (EC) is taken under 
consideration as a water insoluble polymer because 
of the hydrophobic substituent’s (ethyl-). This poly-
mer has been used mainly to form films for the man-
ufacture of oral extended release dosage forms like 
granules, pellets, microcapsules and film tablets. A 
second polymer like hydroxy propyl cellulose has 
been admixed to change the release properties by 
providing hydrated channels for drug release. Mix-
tures of varied proportions of polymers with differ-
ent permeation characteristics could provide an hon-
est range of release rates of a drug by changing the 
diffusivity of the drug through a polymer barrier.[3] 
DM, simply mentioned as diabetes, may be a group of 
metabolic diseases during which an individual has 
high level of blood glucose. The possible causative 
reason maybe that the body doesn't produce enough 
insulin, or cells don't answer the insulin that's pro-
duced by the pancreatic cells. Metformin hydrochlo-
ride is that the first-line drug of choice for the treat-
ment of type II diabetes, especially, in overweight and 
obese people and people having normal kidney func-
tion. metformin helps to enhance hyperglycemia pri-
marily by suppressing glucose production by the liver 
(hepatic gluconeogenesis). It does activate adenosine 
monophosphate-activated protein kinase, an enzyme 
that plays a crucial role in insulin signalling, main-
tains whole body energy balance, and thus metabo-
lism of glucose and fats takes place. the tradi-
tional sort of Metformin tablets are found to pos-
sess many associated drawbacks like gastrointestinal 
upset, including diarrhoea, cramps, nausea, vomiting, 
and increased flatulence. So on reduce the above 
mentioned side-effects and to reinforce patient com-
pliances, sustained release formulation of Metformin 
was developed.[4] 
Hence, within the present work an effort has been 
made, to formulate the sustained release matrix tab-
lets of Metformin Hydrochloride and tested for con-
trolled delivery of drug using hydroxyl propyl methyl 
cellulose (HPMC) as hydrophilic matrix polymer to-
gether with PVC which acts as hydrophobic poly-
mer, leading to reduction in its dosing frequency of 
metformin and therefore the reby its related side ef-
fects and the release behaviour of the drug is evalu-
ated. 
Metformin is very soluble in water which may ab-
ruptly reduce the sugar level in blood thanks to rapid 
release when administered in normal tablets. gener-
ally, the utmost dosage of Metformin is 2,550 
mg/day. it's administered 2-3 times/day at 
meals within the amount of 500 or 750 mg in tablet. 
However, this sort of administration may cause ab-
rupt change within the blood concentration of the 
drug, which can end in adverse reactions and re-
sistance to the drug. However, being a brief acting 
drug, Metformin requires twice-daily or three-times-
a-day dosing.[4]  
A properly designed sustained release dosage sort 
of Metformin will minimize the fluctuation in blood 
concentration, decreasing the danger of side ef-
fects and can show uniform pharmacological re-
sponse and reduce the frequency of administra-
tion. Therefore, the sustained-release dosage sort 
of Metformin may improve the standard of therapy in 
patients with non-insulin dependent DM. 
The essential objective of any drug therapy is to real-
ize steady state blood or tissue level for an extended 
period, which can be therapeutically effective & non-
toxic. Recently, controlled release and sustained re-
lease drug delivery has become the standards within 
the modern pharmaceutical design and intensive re-
search for achieving better drug product effective-
ness, reliability and safety. Oral sustained release 
drug delivery system (OSRDD) will still account 
for the most important share (up to 80%) of drug de-
livery systems.[5] 
Hydrophilic polymer matrix systems are widely uti-
lized in oral controlled drug delivery due to their flex-
ibility to get a desirable drug release profile, cost ef-
fectiveness, and broad regulatory acceptance. the 
power of the hydrophilic polymer matrices to release 
the entrapped drug in aqueous medium and to man-
age the discharge of such drug by control of swelling 
and cross linking makes them particularly suitable 
for controlled release application. 
Oral administration has long been the foremost con-
venient & commonly employed route of drug deliv-
ery thanks to its simple administration, high patient 
compliance & flexibility within the design of dosage 
form. Hydrophilic polymers are getting very fashion-
able in formation of SR/CR tablets. These polymers 
absorb a big amount of water on coming in 
touch with either the dissolution media or biological 
fluids to make a gel. Because the dissolution medium 
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or biological fluids penetrate the matrix, polymer ma-
terial swells & drug molecule begin to maneuver out 
of the system by diffusion at a rate determined by the 
character and composition of polymer. Due 
to their simple preparation, ability to accommo-
date great deal of drug & minimum influence exerted 
by the processing variables on their release rate, hy-
drophilic matrices are increasingly becoming popular 
for oral sustained / controlled drug delivery. During 
the last several years, hydrophilic polymers espe-
cially cellulose & its derivatives are studied as hydro-
philic swellable matrices within the design of oral SR 
/CR systems. The water swellable cellulose ethers 
e.g., Hydroxy Propyl Methyl Cellulose (HPMC) and pH 
independent hydrophilic propenoic acid derivatives 
are mainly getting used for this purpose.[6] 
MATERIALS AND METHODS 
Metformin HCl was obtained from Harman Finochem 
Ltd, Aurangabad India. Dicalcium phosphate anhy-
drous BP/Ph.Eur (granular) obtained from Rhodia 
Caers, Mumbai Pre gelatinized starch. BP/Ph.Eur, Hy-
droxy propyl methyl cellulose K200M BP/Ph.Eur, 
Stearic acid BP/Ph.Eur. Povidone BP/Ph.Eur (K90F) 
Colloidal anhydrous silica BP/Ph.Eur Magnesium 
stearate BP/Ph.Eur is obtained from DKSH India Pvt. 
Ltd, Chennai. 
Study of physical interaction between drug and 
polymer 
Infrared spectrum was taken by scanning the sam-
ples of pure drug and the polymers individually over 
a wave number range of 4000 to 400 cm–1 using Fou-
rier transform infrared spectrophotometer (FT-IR, 
Shimadzu 8400S, Shimadzu, Japan). The change in 
spectra of the drug in the presence of polymer was in-
vestigated which indicates the physical interaction of 
drug molecule with the polymer. 
Preparation of Metformin hydrochloride matrix 
tablets 
All Materials are dispensed as per the approved work 
order Sift API through #20 mesh, Hypromellose 
K200M, Dicalcium phosphate anhydrous and PVP K 
90 through #40 mesh and collect separately in poly-
ethylene bag. Load the sifted materials in RMG and 
mix it for 10 minutes at impeller slow speed Add melt 
stearic acid with slow impeller speed and chopper off 
for 15 sec. Dissolve PVP K90 in the Water by the help 
of mechanical stirrer. Add the binder solution to the 
above mix at impeller medium speed for 5 minutes 
and continue with chopper medium speed for 3 
minutes. Use additional quantity of purified water if 
required and continue mixing till proper consistency 
of wet mass is achieved. Dry the granules with inlet 
temperature 50°C to 55°C till the LOD limit in the 
range of 2-3% w/w. Sift the dried granules through 
#20mesh and mill the retentions through 2.0mm 
screen fitted to the Multimill and knives forward di-
rection. Sift the milled granules through #20mesh. 
Prelubricate the sized granules with Aerosil-200 
(sifted through #40 meshes) and Hypromellose 
K200M for 5 minutes and lubricate with magnesium 
stearate (sifted through #60 mesh) for 3 minutes in 
Octagonal blender. Tablets were compressed[7]. All 
the tablets were stored in airtight containers for fur-
ther study. Prior to compression, granules were eval-
uated for their flow and compressibility characteris-
tics. 
Pre formulation studies 
The pure drug were evaluated for pre formulation 
studies like organoleptic properties in that colour, 
taste and odour then melting point determination, 
particle size distribution of pure drug, loss on drying, 
determination of λ max, flow properties of API like 
bulk density, tapped density, compressibility index, 
hausner’s ratio and drug excipients compatibility 
study. 
Evaluation of granules 
The granules were evaluated for angle of repose, 
loose bulk density (LBD), tapped bulk density (TBD), 
compressibility index and drug content. Angle of re-
pose decided by funnel method. Bulk density and 
tapped density were determined by cylinder method, 
and Carr’s index (CI) was calculated using the subse-
quent equation. 𝐶𝑎𝑟𝑟`𝑠 𝐼𝑛𝑑𝑒𝑥 = (
𝑇𝐵𝐷−𝐿𝐵𝐷
𝑇𝐵𝐷
) × 100. 
Hausner's ratio was associated with interparticle 
friction and will be wont to predict powder flow 
properties. Hausner's values of the prepared gran-
ules ranged from 1.12 to 1.25 was thought to 
point good flow properties 
In vitro drug release studies 
Drug release studies were conducted using USP- Type 
II apparatus, paddle type (Electrolab, Mumbai, India) 
at a rotational speed of 50 rpm at 37±0.5º. The disso-
lution media used were 1000 ml of 0.1 mol/l HCl for 
first 2 h followed by pH 6.8phosphate buffer solution 
for 12 h. Sink condition was maintained for the whole 
experiment. Samples (10 ml) were withdrawn at reg-
ular intervals and the same volume of pre-warmed 
(37±0.5º) fresh dissolution medium was replaced to 
maintain the volume constant. The samples with-
drawn were filtered through a 0.45 μ membrane filter 
(Nunc, New Delhi, India) and the drug content in each 
sample was analyzed after suitable dilution with a UV 
spectrophotometer (Shimadzu UV-1700) at 233 nm. 
The dissolution test was performed in triplicate. Drug 
dissolved at specified time periods was plotted as cu-
mulative percent release versus time (h) curve. 
Kinetic Analysis of release data: 
The release data obtained were treated consistent 
with zero-order (𝑅 = 𝐾1𝑡), first-order (𝑅 = 𝐾1𝑡), 
Higuchi (𝑅 = 𝐾3√𝑡), Korsmeyer-Peppas (log 𝑅 =
𝐿𝑜𝑔 𝐾4 + 𝑛 𝐿𝑜𝑔 𝑡) equation, Hixson–Crowell equa-
tions ((𝑈𝑅)
1
3
= 𝐾5𝑡) to seek out the equation 
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with the simplest fit. Where R and UR are the re-
leased and unreleased percentages, respectively, at 
time (t); k1, k2, k3, k4, and k5 are the speed constants 
of zero-order, first-order, Higuchi matrix, Peppas-
Korsmeyer, and Hixon-Crowell model, respec-
tively. so as to match the discharge profile of vari-
ous formulas with possible difference in release 
mechanisms (n values), a mean dissolution time 
(MDT) was calculated using Equation. 𝑀𝐷𝑇 =
(
𝑛
𝑛+1
)𝐾−1
𝑛
 Where n = release exponent and K= release 
rate constant. 
Statistical Analysis 
Moore and Flanner proposed a model independent 
mathematical approach was used for comparison of 
dissolution profile of selected formulation with mar-
keted product. The dissolution profiles were com-
pared by using two factors, F1 (Dissimilarity factor) 
and F2 (Similarity factor). When the 2 profiles are 
identical, F2=100. FDA has set a public standard of F2 
value between 50-100 indicate similarity of two dis-
solution profiles, and ensures equivalence of the per-
formances of the 2 products[9]. F1 value above 15 to 
point dissimilarity.[14]  
RESULT AND DISCUSSION 
In the preformulation studies color, taste and odor of 
pure drug was observed within the specifications 
(Table 2). Melting of active pharmaceutical ingredi-
ent was determined by using melting point appa-
ratus, and the results are within the specifications. 
And the particle size of the pure drug of active phar-
maceutical ingredient was found to be within the 
range of 180 – 250 microns. Loss on drying also of API 
was determined by digital moisture balance, the re-
sults are given in the following table. The actual quan-
tity to be dispensed for trail batches was calculated 
base upon the assay (On dried basis) and loss on dry-
ing of API, The λ max of the sample was checked by 
using UV spectrophotometer and it was found at 
233.3nm. Standard calibration curve was prepared 
by preparing different concentrations of active phar-
maceutical ingredient in the range of 2 – 10 mcg/ml. 
then the absorbance of those solutions was scanned 
at 232nm against blank No change in physical ap-
pearance was observed during compatibility studies 
with excipients[12]. The results are given in the table 
below. (Table 3) The drug and exepients are compat-
ible, and suitable to develop the formulation. Based 
on Preformulation data, Hypromellose K200M, Pov-
idone K90 and Stearic acid was taken as drug release 
retardants for formulation of SR matrix tablets of a 
highly water soluble Class III drug. The tablets were 
formulated by wet granulation technology using the 
above mentioned polymers to match the drug release 
with that of marketed product.[8-13] 
Table 2: Preformulation studies of pure drug 
Test Specification Observation 
Color White White 
Taste Bitter Bitter 
Odor Odorless Odorless 
Melting point 222 - 226°c 223°c 
Loss on drying Not more than 0.5% 0.10% 
 
Figure 1: Calibration curve of API 
Table 3: Absorbance of different concentrations of 
pure drug 
S.NO. Conc.(mcg/ml) Absorbance(nm) 
1 2 0.201 
2 4 0.375 
3 6 0.558 
4 8 0.758 
5 10 0.95 
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Table 1: Compositions of different formulations 
 S.no Ingredients F1 F2 F3 F4 F5 F6 F7 
Intragranular materials 
1 API 850 850 850 850 850 850 850 
2 Pregelatinized starch 40 40 40 40 40 40 40 
3 HPMC K200m - 10 20 30 30 30 30 
4 DCP 20 95 70 45 30 15  
5 Stearic acid - - - - 15 30 45 
Binders 
6 PVP K90 20 20 20 20 20 20 20 
7 Stearic acid (melt) 200 100 100 100 100 100 100 
8 Purified water Qs Qs Qs Qs Qs Qs Qs 
Extra granular materials 
9 HPMC K 200 - 15 30 45 45 45 45 
10 Aerosil 10 10 10 10 10 10 10 
11 Magnesium stearate 10 10 10 10 10 10 10 
 Average weight 1150 1150 1150 1150 1150 1150 1150 
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Table 4: Blend flow properties of different formulation 
S.no Formulation Code 
Bulk 
Density 
Tapped 
Density 
Hausner’s 
Ratio 
Compressibility 
Index 
Angle of Repose LOD (%) 
1 F001 0.5 0.625 1.25 20 35 ± 0.65 2.42 
2 F002 0.523 0.689 1.31 24 40 ± 0.72 2.33 
3 F003 0.512 0.625 1.22 18 37 ± 0.77 2.46 
4 F004 0.521 0.671 1.28 22 38 ± 0.29 2.1 
5 F005 0.515 0.662 1.28 22 33 ± 0.81 3.2 
6 F006 0.519 0.659 1.26 21 30 ± 0.72 2.74 
7 F007 0.511 0.625 1.22 18 28 ± 0.29 2.82 
Table 5: Physical parameters of tablets 
Formula-
tion 
Code 
Average Weight 
(mg) 
Thickness 
(in mm) 
Hardness 
(kg/cm2) 
Drug content 
(%) 
Friability (%) 
F = 100 (1-
w0/wt) 
Assay 
(%) 
F1 1148.22.80 7.190.05 180.458 98.880.990 0.174% 98.2 
F2 1150.352.8 7.120.04 19.60.519 99.811.206 0.18% 99.1 
F3 1150.382.8 6.980.07 20.30.435 97.7131.062 0.15% 98.6 
F4 1151.063.4 7.200.02 21.30.65 100.452.458 0.14% 99.3 
F5 1150.43.27 7.210.06 20.650.535 99.690.687 0.16% 99.1 
F6 1151.994.1 6.890.09 19.950.5 99.4970.529 0.19% 99.4 
F7 1150.463.4 6.870.07 20.70.50 101.811.555 0.19% 98.21 
n= 10, All the values are mentioned in average±SD 
Table 6: Invitro release profile of different formulations 
Time (hrs) 
% Amount of drug released 
F001 F002 F003 F004 F005 F006 F007 
0 0 0 0 0 0 0 0 
0.5 62.4 53.5 44.6 36.4 31.1 26.2 23.6 
1 93.1 67.2 61.2 52.1 43.6 38.4 35.5 
2 98 78.6 72.5 65.5 59.1 56.5 49.3 
3 - 88.9 81.2 74.6 70.7 66.4 59.6 
4 - 98.7 90.6 85.7 80.4 76.8 71.7 
5 - 102.1 97.8 92.4 89.6 86.7 79.5 
6 - - 101.7 98.8 96.2 92.3 88.7 
8 - - - 103.5 99.1 98.1 95.8 
10 - - - - 102 100.5 98.5 
*All values are expressed as mean, n = 6 
Table 7: Regression values for various kinetic models of F7 
F7 Zero order First order Higuchi Peppas n 
R2 0.6371 0.9746 0.985 0.991 0.4926 
Table 8: Assessment of similarity and dissimilarity factors 
Time (hours) Reference Product Test product R – T (R – T)2 
0 0 0 0 0 
0.5 21.1 23.6 2.5 6.25 
1 33.4 35.5 2.1 4.41 
2 47.8 49.3 1.5 2.25 
3 56.8 59.6 2.8 7.84 
4 68.2 71.7 3.5 12.25 
5 78.3 79.5 1.2 1.44 
6 87.4 88.7 1.3 1.69 
8 93.7 95.8 2.1 4.41 
10 97.2 98.5 1.3 1.69 
F1 3.1 
F2 81.16 
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Figure 2: IR Spectra of API 
 
Figure 3: IR Spectra of physical mix 
All the physico chemical properties of granules (bulk 
density, tapped density, angle of repose, Carr’s index, 
and Hausner ratios) were determined. The results are 
summarized in the following (Table 4).  
Compressibility index of all the formulations are 
measured and found to be 20%, 24%, 18%, 22%, 
22%, 18% respectively for F1, F2, F3, F4, F5, F6, F7. 
From the observations F1, F3, and F7 having fair flow 
property, and F2, F4, F5 and F6 having passable flow 
property. The Hausner’s ratios of all formulations are 
measured and results found to be almost within the 
fair to passable range.[10] The angle of repose of all 
formulations are measured and found to be within 
the range of passable to good All the physical param-
eters of the compressed tablets (thickness, hardness, 
friability and weight variation) were measured and 
the results are summarized in the (Table 5).  
 
Figure 4: Invitro release profile of different formula-
tions 
 
Figure 5: First order release kinetic profile of different 
formulations 
 
Figure 6: Higuchi kinetic release profile of different 
formulations 
 
Figure 7: Korsermeyer – peppas release profile of dif-
ferent formulations 
 
Figure 8: Comparative dissolution profile of F7 and 
reference product 
The matrix tablets of various batches formulated 
were evaluated for test such as uniformity of weight, 
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hardness, thickness, friability and drug content. The 
weight variation tests were performed according to 
as per procedure given in British pharmacopoeia. All 
formulations are found to be satisfactory. The thick-
ness of the matrix tablet was found to be in the range 
of 6.7 to 7.2 mm. The hardness of all batches ranged 
from 17.0-22.0 KP. Another measure of tablet 
strength is friability. The friability of all formulation 
ranged from (0.17 % to 0.19%) which was below 1% 
limit as per the British pharmacopoeia indicating that 
the friability is within the specification limit.  
The sustained release tablet was formulated to re-
lease the drug up to 10 hrs by varying polymer and 
Stearic acid concentration. 
In formulation F1 melt stearic acid (hydrophobic 
agent) only used as drug release retarding agent 
without using of HPMC K200M. During dissolution 
studies fast release of drug was observed, 99% of 
drug released within 2 hours. So the release rate was 
not satisfactory  
In formulation F2 3% HPMC K200M (was used along 
with melt Stearic acid. The drug release was re-
tarded up to 5 hours, but the release rate profile was 
not satisfactory, 
In formulation F3, F4, 6% and 9% HPMC was used 
along with melt Stearic acid, the drug release was 
controlled up to 8 hours, but the release rate was not 
matched with the reference product and also with IP 
specifications. 
From formulation F4 to F7 1%, 2.5%, 4% Stearic acid 
was added intra granularly, the drug release was re-
tarded up to 10 hours and the release profile of F7 
was almost matched with the reference product. The 
similarity factor was observed 81.16%. 
In vitro release study data indicates that duration of 
release of drug is dependent on the percentage of se-
lected polymer and Stearic acid used in the formula-
tions and, an increase in the polymer concentration 
not only causes increase in the viscosity of the gel but 
also leads to formation of gel layer with a longer dif-
fusion path and the Stearic acid induces the hydro-
phobicity. This leads to a decrease in the diffusion of 
the drug and therefore a reduction in the drug re-
lease rate (Table 6). 
Regression values for determined the various kinetic 
models of F7 (Table 7)  
From the dissolution profiles, test product drug re-
lease found almost same as reference (Table 8)  
Stability is an important parameter evaluated for the 
formulations to assess the stability of the drug in the 
formulation at the probable storage conditions. 
The optimized formula Tablets were packed in 
PVC/PVDC clear Aluminium blisters and charged for 
stability as per ICH guidelines given in (Table 1) at 
40◦  C/75%RH (1,2,3,6 month) Then the samples 
were tested for assay, dissolution and related sub-
stances. 
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